Matrix metalloproteinases and their tissue inhibitors in gastric cancer as molecular markers

Journal of Cancer Research and Therapeutics

Volumn 9, Issue 3, 2013, Pages 356-363

  Sampieri, Clara L ^a   León Córdoba, Kenneth ^b   Remes Troche, José María ^a  

^a UNIVERSIDAD VERACRUZANA   (Mexico)

^b Dr Miguel Dorantes Mesa Hospital   (Mexico)

Author keywords

Gastric cancer; matrix metalloproteinases; molecular markers; tissue inhibitors of matrix metalloproteinases

Indexed keywords

CD147 ANTIGEN; COLLAGENASE 3; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 15; MATRIX METALLOPROTEINASE 16; MATRIX METALLOPROTEINASE 17; MATRIX METALLOPROTEINASE 19; MATRIX METALLOPROTEINASE 20; MATRIX METALLOPROTEINASE 26; NERVE GROWTH FACTOR; NEUTROPHIL COLLAGENASE; STROMELYSIN; STROMELYSIN 2; STROMELYSIN 3; THROMBOSPONDIN 1; THROMBOSPONDIN 2; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

CANCER MORTALITY; CANCER RISK; CANCER STAGING; CELL SURVIVAL; DISTANT METASTASIS; ENDOCYTOSIS; EPITHELIAL MESENCHYMAL TRANSITION; FOLLOW UP; HUMAN; IMMUNE RESPONSE; LYMPH NODE METASTASIS; OXIDATIVE STRESS; PERITONEUM LAVAGE; PERITONEUM METASTASIS; PROMOTER REGION; PROTEIN POLYMORPHISM; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; TUMOR INVASION;

GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MATRIX METALLOPROTEINASES; NEOPLASM STAGING; PROGNOSIS; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84885637514     PISSN: 09731482     EISSN: 19984138     Source Type: Journal    
DOI: 10.4103/0973-1482.119302     Document Type: Review

References (110)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55: 74-108.
2. Correa P. A human model of gastric carcinogenesis. Cancer Res 1988;48: 3554-60.
3. Kaposztas Z, Kalmar K, Cseke L, Illenyi L, Kelemen D, Horvath OP. Prognostic factors in the surgical treatment of gastric cancer - 10 years experience. Magy Seb 2007;60: 71-8.
4. Rocco A, Nardone G. Diet, H pylori infection and gastric cancer: evidence and controversies. World J Gastroenterol 2007;13: 2901-12.
5. Barstad B, Sorensen TI, Tjonneland A, Johansen D, Becker U, Andersen IB, et al. Intake of wine, beer and spirits and risk of gastric cancer. Eur J Cancer Prev 2005;14: 239-43.
6. Lindblad M, Rodriguez LA, Lagergren J. Body mass, tobacco and alcohol and risk of esophageal, gastric cardia, and gastric non-cardia adenocarcinoma among men and women in a nested case-control study. Cancer Causes Control 2005;16: 285-94.
7. Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum 1994;61: 1-241.
8. Rad R, Dossumbekova A, Neu B, Lang R, Bauer S, Saur D, et al. Cytokine gene polymorphisms influence mucosal cytokine expression, gastric inflammation, and host specific colonisation during Helicobacter pylori infection. Gut 2004;53: 1082-9.
9. Huang S, Li JY, Wu J, Meng L, Shou CC. Mycoplasma infections and different human carcinomas. World J Gastroenterol 2001;7: 266-9.
10. Yang TT, Wang Y, Liu X, Li X, Pang ZC, Luo B. Genotyping of Epstein- Barr virus in Epstein-Barr virus associated gastric carcinoma. Bing Du Xue Bao 2009;25: 29-34.
11. Correa P, Miller MJ. Helicobacter pylori and gastric atrophy - cancer paradoxes. J Natl Cancer Inst 1995;87: 1731-2.
12. Schmitz JM, Stolte M. Gastric polyps as precancerous lesions. Gastrointest Endosc Clin N Am 1997;7: 29-46.
13. Clark GW, Smyrk TC, Burdiles P, Hoeft SF, Peters JH, Kiyabu M, et al. Is Barrett's metaplasia the source of adenocarcinomas of the cardia? Arch Surg 1994;129: 609-14.
14. Cassaro M, Rugge M, Gutierrez O, Leandro G, Graham DY, Genta RM. Topographic patterns of intestinal metaplasia and gastric cancer. Am J Gastroenterol 2000;95: 1431-8.
15. Ming SC, Bajtai A, Correa P, Elster K, Jarvi OH, Munoz N, et al. Gastric dysplasia. Significance and pathologic criteria. Cancer 1984;54: 1794-801.
16. Coffey RJ, Washington MK, Corless CL, Heinrich MC. Menetrier disease and gastrointestinal stromal tumors: Hyper proliferative disorders of the stomach. J Clin Invest 2007;117: 70-80.
17. Karim S, Ali A. Correlation of p53 over-expression and alteration in p53 gene detected by polymerase chain reaction-single strand conformation polymorphism in adenocarcinoma of gastric cancer patients from India. World J Gastroenterol 2009;15: 1381-7.
18. Grace A, Butler D, Gallagher M, Al-Agha R, Xin Y, Leader M, et al. APC gene expression in gastric carcinoma: An immunohistochemical study. Appl Immunohistochem Mol Morphol 2002;10: 221-4.
19. Mattar R, Nonogaki S, Silva C, Alves V, Gama-Rodrigues JJ. P53 and Rb tumor suppressor gene alterations in gastric cancer. Rev Hosp Clin Fac Med Sao Paulo 2004;59: 172-80.
20. Mayrbaeurl B, Keller G, Schauer W, Burgstaller S, Czompo M, Hoebling W, et al. Germline mutation of the E-cadherin gene in three sibling cases with advanced gastric cancer: Clinical consequences for the other family members. Eur J Gastroenterol Hepatol 2010;22:306-10.
21. Starostik P, Greiner A, Schultz A, Zettl A, Peters K, Rosenwald A, et al. Genetic aberrations common in gastric high-grade large B-cell lymphoma. Blood 2000;95: 1180-7.
22. Yonemura Y, Ninomiya I, Ohoyama S, Kimura H, Yamaguchi A, Fushida S, et al. Expression of c-erbB-2 oncoprotein in gastric carcinoma. Immunoreactivity for c-erbB-2 protein is an independent indicator of poor short-term prognosis in patients with gastric carcinoma. Cancer 1991;67: 2914-8.
23. Park TJ, Han SU, Cho YK, Paik WK, Kim YB, Lim IK. Methylation of O(6)-methylguanine-DNA methyltransferase gene is associated significantly with K-ras mutation, lymph node invasion, tumor staging, and disease free survival in patients with gastric carcinoma. Cancer 2001;92: 2760-8.
24. Hara T, Ooi A, Kobayashi M, Mai M, Yanagihara K, Nakanishi I. Amplification of c-myc, K-sam, and c-met in gastric cancers: Detection by fluorescence in situ hybridization. Lab Invest 1998;78: 1143-53.
25. Zaky AH, Watari J, Tanabe H, Sato R, Moriichi K, Tanaka A, et al. Clinicopathologic implications of genetic instability in intestinal-type gastric cancer and intestinal metaplasia as a precancerous lesion: Proof of field cancerization in the stomach. Am J Clin Pathol 2008;129: 613-21.
26. Borrmann R, Henke F, Lubasch O. Geschwulste des magens und duodenums. Handbuch de speziellen pathologischen anatomie and histologie. 1st ed. Berlin: Springer; 1926. p. 812-1054.
27. Lauren P. The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. An attempt at a histoclinical classification. Acta Pathol Microbiol Scand 1965;64: 31-49.
28. Fuchs CS, Mayer RJ. Gastric carcinoma. N Engl J Med 1995;333: 32-41.
29. Ming SC. Gastric carcinoma. A pathobiological classification. Cancer 1977;39: 2475-85.
30. Goseki N, Takizawa T, Koike M. Differences in the mode of the extension of gastric cancer classified by histological type: New histological classification of gastric carcinoma. Gut 1992;33: 606-12.
31. Hamilton SR, Aaltonen LA. World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Digestive System. 1st ed. Lyon: IARC, Press; 2000. p. 37-67.
32. Sobin L, Gospodarowick M, Wittekind C. Digestive system tumours: Stomach. TNM Classification of Malignant Tumors. 7th ed. Oxford: Wiley-Blackwell; 2010. p. 73-7.
33. Tay ST, Leong SH, Yu K, Aggarwal A, Tan SY, Lee CH, et al. A combined comparative genomic hybridization and expression microarray analysis of gastric cancer reveals novel molecular subtypes. Cancer Res 2003;63: 3309-16.
34. Huntsman DG, Carneiro F, Lewis FR, MacLeod PM, Hayashi A, Monaghan KG, et al. Early gastric cancer in young, asymptomatic carriers of germline E-cadherin mutations. N Engl J Med 2001;344: 1904-9.
35. Kim IJ, Kang HC, Shin Y, Park HW, Jang SG, Han SY, et al. A TP53- truncating germline mutation (E287X) in a family with characteristics of both hereditary diffuse gastric cancer and Li-Fraumeni syndrome. J Hum Genet 2004;49: 591-5.
36. Moutinho C, Mateus AR, Milanezi F, Carneiro F, Seruca R, Suriano G. Epidermal growth factor receptor structural alterations in gastric cancer. BMC Cancer 2008;8: 10.
37. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2: 161-74.
38. Puente XS, Sanchez LM, Overall CM, Lopez-Otin C. Human and mouse proteases: A comparative genomic approach. Nat Rev Genet 2003;4: 544-58.
39. Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: Biological actions and therapeutic opportunities. J Cell Sci 2002;115: 3719-27.
40. Gomis-Ruth FX. Structural aspects of the metzincin clan of metalloendopeptidases. Mol Biotechnol 2003;24: 157-202.
41. Overall CM, Tam EM, Kappelhoff R, Connor A, Ewart T, Morrison CJ, et al. Protease degradomics: Mass spectrometry discovery of protease substrates and the CLIP-CHIP, a dedicated DNA microarray of all human proteases and inhibitors. Biol Chem 2004;385: 493-504.
42. Overall CM, Lopez-Otin C. Strategies for MMP inhibition in cancer: Innovations for the post-trial era. Nat Rev Cancer 2002;2: 657-72.
43. Freije JM, Balbin M, Pendas AM, Sanchez LM, Puente XS, Lopez-Otin C. Matrix metalloproteinases and tumor progression. Adv Exp Med Biol 2003;532: 91-107.
44. Liotta LA, Kohn EC. The microenvironment of the tumor-host interface. Nature 2001;411: 375-9.
45. Liotta LA, Rao CN, Barsky SH. Tumor invasion and the extracellular matrix. Lab Invest 1983;49: 636-49.
46. Nuttall RK, Pennington CJ, Taplin J, Wheal A, Yong VW, Forsyth PA, et al. Elevated membrane-type matrix metalloproteinases in gliomas revealed by profiling proteases and inhibitors in human cancer cells. Mol Cancer Res 2003;1: 333-45.
47. Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003;33: 49-54.
48. Tierney GM, Griffin NR, Stuart RC, Kasem H, Lynch KP, Lury JT, et al. A pilot study of the safety and effects of the matrix metalloproteinase inhibitor marimastat in gastric cancer. Eur J Cancer 1999;35: 563-8.
49. Bramhall SR, Hallissey MT, Whiting J, Scholefield J, Tierney G, Stuart RC, et al. Marimastat as maintenance therapy for patients with advanced gastric cancer: A randomized trial. Br J Cancer 2002;86: 1864-70.
50. Takagi S, Simizu S, Osada H. RECK negatively regulates matrix metalloproteinase-9 transcription. Cancer Res 2009;69: 1502-8.
51. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001;17: 463-516.
52. Lopez-Otin C, Overall CM. Protease degradomics: A new challenge for proteomics. Nat Rev Mol Cell Biol 2002;3: 509-19.
53. Llano E, Pendas AM, Knauper V, Sorsa T, Salo T, Salido E, et al. Identification and structural and functional characterization of human enamelysin (MMP-20). Biochemistry 1997;36: 15101-8.
54. Loffek S, Zigrino P, Angel P, Anwald B, Krieg T, Mauch C. High invasive melanoma cells induce matrix metalloproteinase-1 synthesis in fibroblasts by interleukin-1alpha and basic fibroblast growth factormediated mechanisms. J Invest Dermatol 2005;124: 638-43.
55. Cowden Dahl KD, Zeineldin R, Hudson LG. PEA3 is necessary for optimal epidermal growth factor receptor-stimulated matrix metalloproteinase expression and invasion of ovarian tumor cells. Mol Cancer Res 2007;5: 413-21.
56. Park MJ, Kwak HJ, Lee HC, Yoo DH, Park IC, Kim MS, et al. Nerve growth factor induces endothelial cell invasion and cord formation by promoting matrix metalloproteinase-2 expression through the phosphatidylinositol 3-kinase/Akt signaling pathway and AP-2 transcription factor. J Biol Chem 2007;282: 30485-96.
57. Toschi E, Barillari G, Sgadari C, Bacigalupo I, Cereseto A, Carlei D, et al. Activation of matrix-metalloproteinase-2 and membranetype- 1-matrix-metalloproteinase in endothelial cells and induction of vascular permeability in vivo by human immunodeficiency virus-1 Tat protein and basic fibroblast growth factor. Mol Biol Cell 2001;12: 2934-46.
58. Udayakumar TS, Stratton MS, Nagle RB, Bowden GT. Fibroblast growth factor-1 induced promatrilysin expression through the activation of extracellular-regulated kinases and STAT3. Neoplasia 2002;4: 60-7.
59. Garcia-Alvarez J, Ramirez R, Sampieri CL, Nuttall RK, Edwards DR, Selman M, et al. Membrane type-matrix metalloproteinases in idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2006;23: 13-21.
60. Bond M, Fabunmi RP, Baker AH, Newby AC. Synergistic up regulation of metalloproteinase-9 by growth factors and inflammatory cytokines: An absolute requirement for transcription factor NF-kappa B. FEBS Lett 1998;435: 29-34.
61. Suzuki S, Sato M, Senoo H, Ishikawa K. Direct cell-cell interaction enhances pro-MMP-2 production and activation in co-culture of laryngeal cancer cells and fibroblasts: Involvement of EMMPRIN and MT1-MMP. Exp Cell Res 2004;293: 259-66.
62. Chen YJ, Huang CH, Lee IC, Lee YT, Chen MH, Young TH. Effects of cyclic mechanical stretching on the mRNA expression of tendon/ligament-related and osteoblast-specific genes in human mesenchymal stem cells. Connect Tissue Res 2008;49: 7-14.
63. Fisher GJ, Quan T, Purohit T, Shao Y, Cho MK, He T, et al. Collagen fragmentation promotes oxidative stress and elevates matrix metalloproteinase-1 in fibroblasts in aged human skin. Am J Pathol 2009;174: 101-14.
64. Rutter JL, Mitchell TI, Buttice G, Meyers J, Gusella JF, Ozelius LJ, et al. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res 1998;58: 5321-5.
65. Sugimoto M, Furuta T, Kodaira C, Nishino M, Yamade M, Ikuma M, et al. Polymorphisms of matrix metalloproteinase-7 and chymase are associated with susceptibility to and progression of gastric cancer in Japan. J Gastroenterol 2008;43: 751-61.
66. Zhang J, Jin X, Fang S, Wang R, Li Y, Wang N, et al. The functional polymorphism in the matrix metalloproteinase-7 promoter increases susceptibility to esophageal squamous cell carcinoma, gastric cardiac adenocarcinoma and non-small cell lung carcinoma. Carcinogenesis 2005;26: 1748-53.
67. Matsumura S, Oue N, Nakayama H, Kitadai Y, Yoshida K, Yamaguchi Y, et al. A single nucleotide polymorphism in the MMP-9 promoter affects tumor progression and invasive phenotype of gastric cancer. J Cancer Res Clin Oncol 2005;131: 19-25.
68. Tang Y, Zhu J, Chen L, Zhang S, Lin J. Associations of matrix metalloproteinase-9 protein polymorphisms with lymph node metastasis but not invasion of gastric cancer. Clin Cancer Res 2008;14: 2870-7.
69. Zhang J, Jin X, Fang S, Li Y, Wang R, Guo W, et al. The functional SNP in the matrix metalloproteinase-3 promoter modifies susceptibility and lymphatic metastasis in esophageal squamous cell carcinoma but not in gastric cardiac adenocarcinoma. Carcinogenesis 2004;25: 2519-24.
70. Puente XS, Pendas AM, Llano E, Velasco G, Lopez-Otin C. Molecular cloning of a novel membrane-type matrix metalloproteinase from a human breast carcinoma. Cancer Res 1996;56: 944-9.
71. Sirum KL, Brinckerhoff CE. Cloning of the genes for human stromelysin and stromelysin 2: Differential expression in rheumatoid synovial fibroblasts. Biochemistry 1989;28: 8691-8.
72. Velasco G, Pendas AM, Fueyo A, Knauper V, Murphy G, Lopez-Otin C. Cloning and characterization of human MMP-23, a new matrix metalloproteinase predominantly expressed in reproductive tissues and lacking conserved domains in other family members. J Biol Chem 1999;274: 4570-6.
73. Sottrup-Jensen L, Birkedal-Hansen H. Human fibroblast collagenasealpha- macroglobulin interactions. Localization of cleavage sites in the bait regions of five mammalian alpha-macroglobulins. J Biol Chem 1989;264: 393-401.
74. Yang Z, Strickland DK, Bornstein P. Extracellular matrix metalloproteinase 2 levels are regulated by the low density lipoprotein-related scavenger receptor and thrombospondin 2. J Biol Chem 2001;276: 8403-8.
75. Bein K, Simons M. Thrombospondin type 1 repeats interact with matrix metalloproteinase 2. Regulation of metalloproteinase activity. J Biol Chem 2000;275: 32167-73.
76. Rodriguez-Manzaneque JC, Lane TF, Ortega MA, Hynes RO, Lawler J, Iruela-Arispe ML. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci U S A 2001;98: 12485-90.
77. Yu WH, Yu S, Meng Q, Brew K, Woessner JF Jr. TIMP-3 binds to sulfated glycosaminoglycans of the extracellular matrix. J Biol Chem 2000;275: 31226-32.
78. Llano E, Pendas AM, Freije JP, Nakano A, Knauper V, Murphy G, et al. Identification and characterization of human MT5-MMP, a new membrane-bound activator of progelatinase a overexpressed in brain tumors. Cancer Res 1999;59: 2570-6.
79. De la Pena S, Sampieri CL, Leon-Cordoba K. [Matrix metalloproteases as molecular markers in gastric cancer]. Med Clin (Barc) 2010;134: 123-6.
80. Sugano H, Nakamura K, Kato Y. Pathological studies of human gastric cancer. Acta Pathol Jpn 1982;32 Suppl 2: 329-47.
81. Zhang JF, Zhang YP, Hao FY, Zhang CX, Li YJ, Ji XR. DNA ploidy analysis and expression of MMP-9, TIMP-2, and E-cadherin in gastric carcinoma. World J Gastroenterol 2005;11: 5592-600.
82. Lee KH, Shin SJ, Kim KO, Kim MK, Hyun MS, Kim TN, et al. Relationship between E-cadherin, matrix metalloproteinase-7 gene expression and clinicopathological features in gastric carcinoma. Oncol Rep 2006;16: 823-30.
83. Mori M, Mimori K, Shiraishi T, Fujie T, Baba K, Kusumoto H, et al. Analysis of MT1-MMP and MMP2 expression in human gastric cancers. Int J Cancer 1997;74: 316-21.
84. Zhou Y, Li G, Wu J, Zhang Z, Wu Z, Fan P, et al. Clinicopathological significance of E-cadherin, VEGF, and MMPs in gastric cancer. Tumour Biol 2010;31: 549-58.
85. Allgayer H, Babic R, Beyer BC, Grutzner KU, Tarabichi A, Schildberg FW, et al. Prognostic relevance of MMP-2 (72-kD collagenase IV) in gastric cancer. Oncology 1998;55: 152-60.
86. Zhao ZS, Chu YQ, Ye ZY, Wang YY, Tao HQ. Over expression of matrix metalloproteinase 11 in human gastric carcinomas and its clinicopathologic significance. Hum Pathol 2011;41: 686-96.
87. De Mingo M, Moran A, Sanchez-Pernaute A, Iniesta P, Diez-Valladares L, Perez-Aguirre E, et al. Expression of MMP-9 and TIMP-1 as prognostic markers in gastric carcinoma. Hepatogastroenterology 2007;54: 315-9.
88. Elnemr A, Yonemura Y, Bandou E, Kinoshita K, Kawamura T, Takahashi S, et al. Expression of collagenase-3 (matrix metalloproteinase-13) in human gastric cancer. Gastric Cancer 2003;6: 30-8.
89. Sier CF, Kubben FJ, Ganesh S, Heerding MM, Griffioen G, Hanemaaijer R, et al. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer 1996;74: 413-7.
90. Shim KN, Jung SA, Joo YH, Yoo K. Clinical significance of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in gastric cancer. J Gastroenterol 2007;42: 120-8.
91. Jian P, Yanfang T, Zhuan Z, Jian W, Xueming Z, Jian N. MMP28 (epilysin) as a novel promoter of invasion and metastasis in gastric cancer. BMC Cancer 2011;11: 200.
92. Yoshikawa T, Tsuburaya A, Kobayashi O, Sairenji M, Motohashi H, Yanoma S, et al. Intratumoral concentrations of tissue inhibitor of matrix metalloproteinase 1 in patients with gastric carcinoma a new biomartker for invasion and its impact on survival. Cancer 2001;91: 1739-44.
93. Yonemura Y, Fujimura T, Ninomiya I, Kim BS, Bandou E, Sawa T, et al. Prediction of peritoneal micrometastasis by peritoneal lavaged cytology and reverse transcriptase-polymerase chain reaction for matrix metalloproteinase-7 mRNA. Clin Cancer Res 2001;7: 1647-53.
94. Wu CY, Wu MS, Chiang EP, Chen YJ, Chen CJ, Chi NH, et al. Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution. Clin Cancer Res 2007;13: 2054-60.
95. Yoshikawa T, Cho H, Tsuburaya A, Kobayashi O. Impact of plasma tissue inhibitor of metalloproteinase-1 on long-term survival in patients with gastric cancer. Gastric Cancer 2009;12: 31-6.
96. Yonemura Y, Endou Y, Fujita H, Fushida S, Bandou E, Taniguchi K, et al. Role of MMP-7 in the formation of peritoneal dissemination in gastric cancer. Gastric Cancer 2000;3: 63-70.
97. Murray GI, Duncan ME, Arbuckle E, Melvin WT, Fothergill JE. Matrix metalloproteinases and their inhibitors in gastric cancer. Gut 1998;43: 791-7.
98. Cheng P, Jiang FH, Zhao LM, Dai Q, Yang WY, Zhu LM, et al. Human macrophage metalloelastase correlates with angiogenesis and prognosis of gastric carcinoma. Dig Dis Sci 2010;55: 3138-46.
99. Honda M, Mori M, Ueo H, Sugimachi K, Akiyoshi T. Matrix metalloproteinase-7 expression in gastric carcinoma. Gut 1996;39: 444-8.
100. Okayama H, Kumamoto K, Saitou K, Hayase S, Kofunato Y, Sato Y, et al. CD44v6, MMP-7 and nuclear Cdx2 are significant biomarkers for prediction of lymph node metastasis in primary gastric cancer. Oncol Rep 2009;22: 745-55.
101. Mimori K, Fukagawa T, Kosaka Y, Ishikawa K, Iwatsuki M, Yokobori T, et al. A large-scale study of MT1-MMP as a marker for isolated tumor cells in peripheral blood and bone marrow in gastric cancer cases. Ann Surg Oncol 2008;15: 2934-42.
102. Chen JQ, Zhan WH, He YL, Peng JS, Wang JP, Cai SR, et al. Expression of heparanase gene, CD44v6, MMP-7 and nm23 protein and their relationship with the invasion and metastasis of gastric carcinomas. World J Gastroenterol 2004;10: 776-82.
103. Zhao ZS, Zhou JL, Yao GY, Ru GQ, Ma J, Ruan J. Correlative studies on bFGF mRNA and MMP-9 mRNA expressions with microvascular density, progression, and prognosis of gastric carcinomas. World J Gastroenterol 2005;11: 3227-33.
104. Zhao ZS, Chu YQ, Ye ZY, Wang YY, Tao HQ. Over expression of matrix metalloproteinase 11 in human gastric carcinomas and its clinicopathologic significance. Hum Pathol 2010;41: 686-96.
105. Mroczko B, Lukaszewicz-Zajac M, Gryko M, Kedra B, Szmitkowski M. Clinical significance of serum levels of matrix metalloproteinase 2 (MMP-2) and its tissue inhibitor (TIMP-2) in gastric cancer. Folia Histochem Cytobiol 2011;49: 125-31.
106. Yoshikawa T, Saitoh M, Tsuburaya A, Kobayashi O, Sairenji M, Motohashi H, et al. Tissue inhibitor of matrix metalloproteinase-1 in the plasma of patients with gastric carcinoma. A possible marker for serosal invasion and metastasis. Cancer 1999;86: 1929-35.
107. Fujimoto D, Hirono Y, Goi T, Katayama K, Yamaguchi A. Prognostic value of protease-activated receptor-1 (PAR-1) and matrix metalloproteinase-1 (MMP-1) in gastric cancer. Anticancer Res 2008;28: 847-54.
108. Kemik O, Kemik AS, Sumer A, Dulger AC, Adas M, Begenik H, et al. Levels of matrix metalloproteinase-1 and tissue inhibitors of metalloproteinase-1 in gastric cancer. World J Gastroenterol 2011;17: 2109-12.
109. Moore HM, Kelly AB, Jewell SD, McShane LM, Clark DP, Greenspan R, et al. Biospecimen reporting for improved study quality (BRISQ). J Proteome Res 2011;10: 3429-38.
110. Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting recommendations for tumor marker prognostic studies (REMARK): Explanation and elaboration. BMC Med 2012;10: 51.